

Satoshi Ebata

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/289931/publications.pdf>

Version: 2024-02-01

20
papers

394
citations

1040056

9
h-index

839539

18
g-index

20
all docs

20
docs citations

20
times ranked

340
citing authors

#	ARTICLE	IF	CITATIONS
1	Percentage of residual B cells after 2 weeks of rituximab treatment predicts the improvement of systemic sclerosis-associated interstitial lung disease. <i>Journal of Dermatology</i> , 2022, 49, 179-183.	1.2	6
2	Predictors of rituximab effect on modified Rodnan skin score in systemic sclerosis: a machine-learning analysis of the DesiReS trial. <i>Rheumatology</i> , 2022, 61, 4364-4373.	1.9	18
3	Serum C-X-C Chemokine Ligand 1 Levels in Patients with Systemic Sclerosis: Relationship of Clinical and Laboratory Observations to Anti-CD20 Monoclonal Antibody Administration. <i>Life</i> , 2022, 12, 646.	2.4	1
4	Autoantibody Landscape Revealed by Wet Protein Array: Sum of Autoantibody Levels Reflects Disease Status. <i>Frontiers in Immunology</i> , 2022, 13, .	4.8	7
5	Safety and efficacy of rituximab in systemic sclerosis (DESIREs): open-label extension of a double-blind, investigator-initiated, randomised, placebo-controlled trial. <i>Lancet Rheumatology</i> , The, 2022, 4, e546-e555.	3.9	21
6	Serum TARC Levels in Patients with Systemic Sclerosis: Clinical Association with Interstitial Lung Disease. <i>Journal of Clinical Medicine</i> , 2021, 10, 660.	2.4	2
7	Development of a prediction model of treatment response in patients with cutaneous arteritis: Insights from a cohort of 33 patients. <i>Journal of Dermatology</i> , 2021, 48, 1021-1026.	1.2	3
8	Safety and efficacy of rituximab in systemic sclerosis (DESIREs): a double-blind, investigator-initiated, randomised, placebo-controlled trial. <i>Lancet Rheumatology</i> , The, 2021, 3, e489-e497.	3.9	105
9	B Cell Depletion Inhibits Fibrosis via Suppression of Profibrotic Macrophage Differentiation in a Mouse Model of Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2021, 73, 2086-2095.	5.6	17
10	Expert-Level Distinction of Systemic Sclerosis from Hand Photographs Using Deep Convolutional Neural Networks. <i>Journal of Investigative Dermatology</i> , 2021, 141, 2536-2539.	0.7	5
11	Interleukin-31 promotes fibrosis and T helper 2 polarization in systemic sclerosis. <i>Nature Communications</i> , 2021, 12, 5947.	12.8	38
12	Increased Red Blood Cell Distribution Width in the First Year after Diagnosis Predicts Worsening of Systemic Sclerosis-Associated Interstitial Lung Disease at 5 Years: A Pilot Study. <i>Diagnostics</i> , 2021, 11, 2274.	2.6	2
13	Interleukin (IL)-17F and IL-17E are related to fibrosis and vasculopathy in systemic sclerosis. <i>Journal of Dermatology</i> , 2020, 47, 1287-1292.	1.2	9
14	Rapid decrease of serum surfactant protein-D levels predicts the reactivity of rituximab therapy in systemic sclerosis-associated interstitial lung disease. <i>Journal of Dermatology</i> , 2020, 47, 796-800.	1.2	4
15	Combined immunosuppressive therapy provides favorable prognosis and increased risk of cytomegalovirus reactivation in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis. <i>Journal of Dermatology</i> , 2020, 47, 483-489.	1.2	22
16	Rituximab therapy is more effective than cyclophosphamide therapy for Japanese patients with anti-topoisomerase I-positive systemic sclerosis-associated interstitial lung disease. <i>Journal of Dermatology</i> , 2019, 46, 1006-1013.	1.2	47
17	Skin thickness score as a surrogate marker of organ involvements in systemic sclerosis: a retrospective observational study. <i>Arthritis Research and Therapy</i> , 2019, 21, 129.	3.5	29
18	Successful treatment with rituximab in a Japanese patient with systemic sclerosis-associated interstitial lung disease resistant to oral steroid and cyclophosphamide. <i>Journal of Dermatology</i> , 2018, 45, e140-e141.	1.2	3

#	ARTICLE	IF	CITATIONS
19	Rapid alteration of serum interleukin-6 levels may predict the reactivity of i.v. cyclophosphamide pulse therapy in systemic sclerosis-associated interstitial lung disease. <i>Journal of Dermatology</i> , 2018, 45, 1221-1224.	1.2	8
20	Contribution of Soluble Forms of Programmed Death 1 and Programmed Death Ligand 2 to Disease Severity and Progression in Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2017, 69, 1879-1890.	5.6	47